Why is celebrating failure in life science just as important as celebrating success?

How do you make the psychological shift from being one expert among many in the room to being a leader of experts?

And what does a near-industry wide clinical failure have to do with a potential new treatment for half a billion osteoarthritis patients?

Today I’m joined by Eliot Forster, CEO of Levicept based just south of Oxford in the UK, looking into novel treatments for the signs and symptoms of osteoarthritis.

About LifeScience ORG

It’s no secret that Europe is a global leader in generating translational science. We’re grateful at LifeScience ORG to have a community of over 400 life science CEOs – leaders driving change in biotech, medtech, techBio and healthcare.

The conversations inside our community – stories of conviction, navigating challenges, and making bold decisions – inspire us every week. To hear the stories, lessons, and experiences of our life science leaders, listen to A Call to Lead @ LifeScience ORG, available on all good podcasting platforms.

Timestamps

1:03 - From Big Pharma to Biotech: Why Cross the Table?

4:33 - The Moment You Decide to Lead

7:41 - The Personal Toll of the CEO Role

9:39 - Practical Habits That Protect Your Bandwidth

11:04 - Leading in a Crowded Capital Environment

13:02 - Transitioning from Expert to Leader of Experts

17:36 - Why Celebrating Failure Is Non-Negotiable in Drug Development

24:40 - The Maturing European Life Science Ecosystem

28:07 - A Novel Approach to Osteoarthritis: From Industry-Wide Failure to Phase 2 Success

35:13 - Optimism as a Professional Imperative in Life Science